未名醫藥(002581.SZ):未名集團被司法拍賣的5829.97萬股已完成過户
格隆匯11月19日丨未名醫藥(002581.SZ)公佈,公司於2021年11月19日收到公司股東北京北大未名生物工程集團有限公司(“未名集團”)和廈門恆興集團有限公司(“廈門恆興”)出具的《山東未名生物醫藥股份有限公司簡式權益變動報吿書》,獲悉未名集團持有的公司5829.97萬股股份因司法拍賣已完成過户登記手續,上述事項導致公司股東權益發生變動。
公司通過中登結算公司系統查詢,廈門恆興通過司法變賣、拍賣合計競得的公司4940萬股股票均已在中國證券登記結算有限責任公司辦理完成過户登記手續,佔公司總股本的7.49%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.